Cooley U: Evaluating the Opportunity for a Reverse Merger

Jan 23 2018

Reverse mergers can be an effective tool for management to increase value and liquidity for companies in need of capital. In the past year, several life sciences companies have successfully accessed public markets through reverse merger transactions. What factors should you consider in evaluating whether a reverse merger is a good option for your company? Join our panel of seasoned dealmakers who have directly led reverse merger transactions.

Discussion topics will include:

  • Assessing whether you are a reverse merger candidate and how to get ready
  • Preparing your financial statements, cap table and corporate governance matters
  • Selecting a target
  • Financing in the context of a reverse merger
  • Achieving success following a reverse merger

Rama Padmanabhan | Partner, Cooley LLP read bio»
Joseph Payne | President, Chief Executive Officer and Chairman of the Board, Arcturus Therapeutics Inc. read bio»
Matt Silverman | Lawyer, Cooley LLP read bio»

11:30AM | Registration Opens, Networking Lunch
12:00PM | Presentation and Q&A
1:00PM | Networking
1:30PM | Program Close

$15 | General Public
$10 | Student
$25 | At the Door
Includes presentation, Q&A, and lunch.

JLABS in San Diego
3210 Merryfield Row
San Diego, CA

Speakers' Biographies:
Rama Padmanabhan | Partner, Cooley LLP
Rama Padmanabhan focuses her practice on all types of public and private merger and acquisition transactions, including options to buy, cross border transactions, joint ventures and other complex transactions. In addition to her M&A practice, Rama has extensive experience in public company representation, emerging company representation, venture capital financings and private and public securities offerings. She has experience representing technology, life sciences and other companies, including software, semi-conductor, biotechnology, medical device, aviation, restaurant, gaming and apparel companies. Rama is a member of the Mergers and Acquisitions Committee of the American Bar Association and is actively involved in the activities and projects of the model asset purchase agreement and corporate governance task forces. Prior to joining Cooley, Rama was an associate with Skadden, Arps, Slate, Meagher & Flom LLP.

Joseph Payne | Chief Executive Officer and Chairman of the Board, Arcturus Therapeutics Inc.
Joseph E. Payne, is President, Chief Executive Officer and Chairman of the Board for Arcturus Therapeutics, Inc. Since inception in 2013, Arcturus has built a diverse early pipeline of seven RNA therapeutic programs (five of which are fully funded through collaborative partnerships with Johnson & Johnson, Takeda, Ultragenyx, and the Cystic Fibrosis Foundation). Joseph’s background includes over 20 years of successful drug discovery experience at Merck Research Labs, DuPont Pharmaceuticals, Bristol-Myers Squibb, Kalypsys, and Nitto as evidenced by over 50 publications and patents, and several investigational new drug (IND) clinical candidates. His academic training includes BYU (magna cum laude, Chemistry and Physics), University of Calgary (Synthetic Organic Chemistry), and MIT Sloan School of Management.

Matt Silverman | Lawyer, Cooley LLP
Matt handles mergers and acquisitions, private equity, securities law, private financing transactions and general corporate matters for both public and private companies. In addition to his transactional practice, Matt is actively engaged in pro bono, having represented numerous clients on immigration law matters and women's rights issues. Prior to joining Cooley, Matthew was an associate with Skadden, Arps, Slate, Meagher & Flom in New York.